Literature DB >> 22987835

Laboratory medicine and medical oncology: the tale of two Cinderellas.

Bohuslav Melichar1.   

Abstract

Cancer represents a leading cause of death in the developed countries. The past 50 years have witnessed major progress in both laboratory medicine and clinical oncology that has translated into improved prognosis of cancer patients. From the humble beginnings as unrelated specialties, major advances in the understanding of molecular bases of cancer progression led to increased interactions between laboratory medicine and clinical (mostly medical) oncology. Laboratory medicine is now an integral part of the management of cancer patients. The many aspects of the role of laboratory medicine in clinical oncology include the determination of biomarkers that are used in establishing the diagnosis, predicting response to therapy or prognosis, study of the host response to tumor growth, detection of treatment toxicity and determining the concentrations of anticancer drugs.

Entities:  

Mesh:

Year:  2013        PMID: 22987835     DOI: 10.1515/cclm-2012-0496

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

Review 1.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

2.  MALDI Orbitrap Mass Spectrometry Profiling of Dysregulated Sulfoglycosphingolipids in Renal Cell Carcinoma Tissues.

Authors:  Robert Jirásko; Michal Holčapek; Maria Khalikova; David Vrána; Vladimír Študent; Zuzana Prouzová; Bohuslav Melichar
Journal:  J Am Soc Mass Spectrom       Date:  2017-03-30       Impact factor: 3.109

3.  Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor.

Authors:  Hana Študentová; Jarmila Indráková; Pavla Petrová; Milan Kamínek; Hana Kalábová; Vlastislav Šrámek; Tomáš Adam; Bohuslav Melichar
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

4.  The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.

Authors:  Weijuan Jia; Jiannan Wu; Haixia Jia; Yaping Yang; Xiaolan Zhang; Kai Chen; Fengxi Su
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

5.  Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.

Authors:  Danian Dai; Bo Chen; Hailin Tang; Bin Wang; Zhiping Zhao; Xiaoming Xie; Weidong Wei
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

Review 6.  ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Authors:  David Vrana; Viktor Hlavac; Veronika Brynychova; Radka Vaclavikova; Cestmir Neoral; Jiri Vrba; Rene Aujesky; Marcel Matzenauer; Bohuslav Melichar; Pavel Soucek
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

7.  Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome.

Authors:  Radmila Lemstrova; Veronika Brynychova; David J Hughes; Viktor Hlavac; Pavel Dvorak; Joanne E Doherty; Helena A Murray; Martin Crockard; Martin Oliverius; Jan Hlavsa; Eva Honsova; Jan Mazanec; Zdenek Kala; Martin Lovecek; Roman Havlik; Jiri Ehrmann; Ondrej Strouhal; Pavel Soucek; Bohuslav Melichar; Beatrice Mohelnikova-Duchonova
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

8.  Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients.

Authors:  Ondrej Fiala; Jindrich Finek; Alexandr Poprach; Bohuslav Melichar; Jindrich Kopecký; Milada Zemanova; Katerina Kopeckova; Tomas Mlcoch; Tomas Dolezal; Lenka Capkova; Tomas Buchler
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.